The Effect of DHEAS on Influenza Vaccination in Aging Adults

OBJECTIVE: To determine whether simultaneous administration of dehydroepiandrosterone sulfate (DHEAS) exhibits adjuvant activity in the immune response of aging humans by supplementing influenza vaccination with the maximum single dose of DHEAS that could be practically injected subcutaneously (appr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American Geriatrics Society (JAGS) 1997-06, Vol.45 (6), p.747-751
Hauptverfasser: Degelau, John, Guay, David, Hallgren, Helen
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 751
container_issue 6
container_start_page 747
container_title Journal of the American Geriatrics Society (JAGS)
container_volume 45
creator Degelau, John
Guay, David
Hallgren, Helen
description OBJECTIVE: To determine whether simultaneous administration of dehydroepiandrosterone sulfate (DHEAS) exhibits adjuvant activity in the immune response of aging humans by supplementing influenza vaccination with the maximum single dose of DHEAS that could be practically injected subcutaneously (approximately 7.5 mg). DESIGN: A randomized, double‐blind, placebo‐controlled trial of DHEAS injection with 1993–94 and 1994–95 influenza vaccine in older subjects. In addition, initial safety, tolerability, and control testing with 1993–94 influenza vaccine was conducted in young subjects. SETTING: An urban primary care geriatrics clinic. PARTICIPANTS: Seventy‐eight older adult volunteers (mean age 78.61 ± 3.43 years, range 73–90 years) and 20 younger controls (
doi_str_mv 10.1111/j.1532-5415.1997.tb01482.x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79065648</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>13670600</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4642-c0ce8903717414fc85cdfd5b0e78c51b7688be5f467d222673034d5389841f603</originalsourceid><addsrcrecordid>eNqVkF1P2zAUhq1pE3SwnzApQhN3yWzHX0GTUMVKAVWAVDak3ViOY4NL6kCciLJfP0eNerE7fGPL5znvOXoAOEIwQ_F8X2WI5jilBNEMFQXPuhIiInC2-QAmu9JHMIEQ4lQwRPbB5xBWECIMhdgDewUSkHE8AT_uHk0ys9boLmls8vNiNl0mjU8uva174_-q5LfS2nnVufjrfDJ9cP4hmVZ93YVD8MmqOpgv430Afp3P7s4u0sXN_PJsukg1YQSnGmojCphzxAkiVguqK1vREhouNEUlZ0KUhlrCeIUxZjyHOaloLgpBkGUwPwDH29zntnnpTejk2gVt6lp50_RB8gIyyoiI4NF_4KrpWx93kxjFBTBHOEInW0i3TQitsfK5dWvVvkkE5eBXruQgUQ4S5eBXjn7lJjZ_HSf05dpUu9ZRaKx_G-sqaFXbVnntwg7DTBQMD9jpFnt1tXl7xwLyar4cXjEh3Sa40JnNLkG1TzIK5FTeX88lXdziP1As5X3-Dx78ooM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>210372712</pqid></control><display><type>article</type><title>The Effect of DHEAS on Influenza Vaccination in Aging Adults</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Degelau, John ; Guay, David ; Hallgren, Helen</creator><creatorcontrib>Degelau, John ; Guay, David ; Hallgren, Helen</creatorcontrib><description>OBJECTIVE: To determine whether simultaneous administration of dehydroepiandrosterone sulfate (DHEAS) exhibits adjuvant activity in the immune response of aging humans by supplementing influenza vaccination with the maximum single dose of DHEAS that could be practically injected subcutaneously (approximately 7.5 mg). DESIGN: A randomized, double‐blind, placebo‐controlled trial of DHEAS injection with 1993–94 and 1994–95 influenza vaccine in older subjects. In addition, initial safety, tolerability, and control testing with 1993–94 influenza vaccine was conducted in young subjects. SETTING: An urban primary care geriatrics clinic. PARTICIPANTS: Seventy‐eight older adult volunteers (mean age 78.61 ± 3.43 years, range 73–90 years) and 20 younger controls (&lt;40 years, means age 32.76 ± 5.39 years) were recruited from clinic and community advertising. Subjects were free of disease or medication known to affect immune function. MEASUREMENTS: Immune responses to vaccine at 0, 2, and 4 weeks were measured by vaccine antigen‐induced lymphoproliferation in peripheral blood mononuclear cells (PBMC) and serum antibody response by hemagglutination inhibition (HI). RESULTS: The maximum DHEAS dose that could be practically administered subcutaneously was 7.5 mg. Baseline DHEAS levels were significantly lower in older adults (52.1 vs 236.4 μg/dL, P &lt; .001). The 1993 old adult DHEAS group HI response tended to be higher for the H3N2 Beijing antigen but not for the H1N1 or B antigen. In subjects with HI titers less then 1:40 for the H3N2 Beijing antigen (n = 29), the post‐vaccination titer response tended to be higher among the 16 subjects who received DHEAS (P = .06). The peak response for the H3N2 antigen was associated with the initial DHEAS serum concentration in the DHEAS and placebo groups (R2 =.22, P = .04 and R2 = .21, P = .06, respectively). No significant differences were found for antibody responses to the H1N1 and B antigens or vaccine‐antigen induced lymphoproliferation. CONCLUSION: A one‐time supplemental dose of DHEAS with influenza vaccination appeared to enhance the specific HI antibody response to the 1993–94 H3N2 antigen in a small group of older adults. These findings were limited to those with lower prevaccination titers and lower DHEAS concentrations. Although clinical implications of these findings for influenza vaccine are uncertain, these results suggest additional detailed immunologic investigations on the role of DHEAS in the aging human immune response are warranted.</description><identifier>ISSN: 0002-8614</identifier><identifier>EISSN: 1532-5415</identifier><identifier>DOI: 10.1111/j.1532-5415.1997.tb01482.x</identifier><identifier>PMID: 9180672</identifier><identifier>CODEN: JAGSAF</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adult ; Aged ; Aging ; Antibody Formation ; Biological and medical sciences ; Dehydroepiandrosterone Sulfate - immunology ; Double-Blind Method ; Epidemiology. Vaccinations ; Female ; General aspects ; Hemagglutination ; Hormones. Endocrine system ; Humans ; Infectious diseases ; Influenza ; Influenza Vaccines - therapeutic use ; Influenza, Human - prevention &amp; control ; Male ; Medical sciences ; Older people ; Pharmacology. Drug treatments ; Placebos ; Retrospective Studies ; Vaccines</subject><ispartof>Journal of the American Geriatrics Society (JAGS), 1997-06, Vol.45 (6), p.747-751</ispartof><rights>1997 The American Geriatrics Society</rights><rights>1997 INIST-CNRS</rights><rights>Copyright Lippincott Williams &amp; Wilkins Jun 1997</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4642-c0ce8903717414fc85cdfd5b0e78c51b7688be5f467d222673034d5389841f603</citedby><cites>FETCH-LOGICAL-c4642-c0ce8903717414fc85cdfd5b0e78c51b7688be5f467d222673034d5389841f603</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1532-5415.1997.tb01482.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1532-5415.1997.tb01482.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2689622$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9180672$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Degelau, John</creatorcontrib><creatorcontrib>Guay, David</creatorcontrib><creatorcontrib>Hallgren, Helen</creatorcontrib><title>The Effect of DHEAS on Influenza Vaccination in Aging Adults</title><title>Journal of the American Geriatrics Society (JAGS)</title><addtitle>J Am Geriatr Soc</addtitle><description>OBJECTIVE: To determine whether simultaneous administration of dehydroepiandrosterone sulfate (DHEAS) exhibits adjuvant activity in the immune response of aging humans by supplementing influenza vaccination with the maximum single dose of DHEAS that could be practically injected subcutaneously (approximately 7.5 mg). DESIGN: A randomized, double‐blind, placebo‐controlled trial of DHEAS injection with 1993–94 and 1994–95 influenza vaccine in older subjects. In addition, initial safety, tolerability, and control testing with 1993–94 influenza vaccine was conducted in young subjects. SETTING: An urban primary care geriatrics clinic. PARTICIPANTS: Seventy‐eight older adult volunteers (mean age 78.61 ± 3.43 years, range 73–90 years) and 20 younger controls (&lt;40 years, means age 32.76 ± 5.39 years) were recruited from clinic and community advertising. Subjects were free of disease or medication known to affect immune function. MEASUREMENTS: Immune responses to vaccine at 0, 2, and 4 weeks were measured by vaccine antigen‐induced lymphoproliferation in peripheral blood mononuclear cells (PBMC) and serum antibody response by hemagglutination inhibition (HI). RESULTS: The maximum DHEAS dose that could be practically administered subcutaneously was 7.5 mg. Baseline DHEAS levels were significantly lower in older adults (52.1 vs 236.4 μg/dL, P &lt; .001). The 1993 old adult DHEAS group HI response tended to be higher for the H3N2 Beijing antigen but not for the H1N1 or B antigen. In subjects with HI titers less then 1:40 for the H3N2 Beijing antigen (n = 29), the post‐vaccination titer response tended to be higher among the 16 subjects who received DHEAS (P = .06). The peak response for the H3N2 antigen was associated with the initial DHEAS serum concentration in the DHEAS and placebo groups (R2 =.22, P = .04 and R2 = .21, P = .06, respectively). No significant differences were found for antibody responses to the H1N1 and B antigens or vaccine‐antigen induced lymphoproliferation. CONCLUSION: A one‐time supplemental dose of DHEAS with influenza vaccination appeared to enhance the specific HI antibody response to the 1993–94 H3N2 antigen in a small group of older adults. These findings were limited to those with lower prevaccination titers and lower DHEAS concentrations. Although clinical implications of these findings for influenza vaccine are uncertain, these results suggest additional detailed immunologic investigations on the role of DHEAS in the aging human immune response are warranted.</description><subject>Adult</subject><subject>Aged</subject><subject>Aging</subject><subject>Antibody Formation</subject><subject>Biological and medical sciences</subject><subject>Dehydroepiandrosterone Sulfate - immunology</subject><subject>Double-Blind Method</subject><subject>Epidemiology. Vaccinations</subject><subject>Female</subject><subject>General aspects</subject><subject>Hemagglutination</subject><subject>Hormones. Endocrine system</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Influenza</subject><subject>Influenza Vaccines - therapeutic use</subject><subject>Influenza, Human - prevention &amp; control</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Older people</subject><subject>Pharmacology. Drug treatments</subject><subject>Placebos</subject><subject>Retrospective Studies</subject><subject>Vaccines</subject><issn>0002-8614</issn><issn>1532-5415</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkF1P2zAUhq1pE3SwnzApQhN3yWzHX0GTUMVKAVWAVDak3ViOY4NL6kCciLJfP0eNerE7fGPL5znvOXoAOEIwQ_F8X2WI5jilBNEMFQXPuhIiInC2-QAmu9JHMIEQ4lQwRPbB5xBWECIMhdgDewUSkHE8AT_uHk0ys9boLmls8vNiNl0mjU8uva174_-q5LfS2nnVufjrfDJ9cP4hmVZ93YVD8MmqOpgv430Afp3P7s4u0sXN_PJsukg1YQSnGmojCphzxAkiVguqK1vREhouNEUlZ0KUhlrCeIUxZjyHOaloLgpBkGUwPwDH29zntnnpTejk2gVt6lp50_RB8gIyyoiI4NF_4KrpWx93kxjFBTBHOEInW0i3TQitsfK5dWvVvkkE5eBXruQgUQ4S5eBXjn7lJjZ_HSf05dpUu9ZRaKx_G-sqaFXbVnntwg7DTBQMD9jpFnt1tXl7xwLyar4cXjEh3Sa40JnNLkG1TzIK5FTeX88lXdziP1As5X3-Dx78ooM</recordid><startdate>199706</startdate><enddate>199706</enddate><creator>Degelau, John</creator><creator>Guay, David</creator><creator>Hallgren, Helen</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>199706</creationdate><title>The Effect of DHEAS on Influenza Vaccination in Aging Adults</title><author>Degelau, John ; Guay, David ; Hallgren, Helen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4642-c0ce8903717414fc85cdfd5b0e78c51b7688be5f467d222673034d5389841f603</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aging</topic><topic>Antibody Formation</topic><topic>Biological and medical sciences</topic><topic>Dehydroepiandrosterone Sulfate - immunology</topic><topic>Double-Blind Method</topic><topic>Epidemiology. Vaccinations</topic><topic>Female</topic><topic>General aspects</topic><topic>Hemagglutination</topic><topic>Hormones. Endocrine system</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Influenza</topic><topic>Influenza Vaccines - therapeutic use</topic><topic>Influenza, Human - prevention &amp; control</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Older people</topic><topic>Pharmacology. Drug treatments</topic><topic>Placebos</topic><topic>Retrospective Studies</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Degelau, John</creatorcontrib><creatorcontrib>Guay, David</creatorcontrib><creatorcontrib>Hallgren, Helen</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American Geriatrics Society (JAGS)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Degelau, John</au><au>Guay, David</au><au>Hallgren, Helen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Effect of DHEAS on Influenza Vaccination in Aging Adults</atitle><jtitle>Journal of the American Geriatrics Society (JAGS)</jtitle><addtitle>J Am Geriatr Soc</addtitle><date>1997-06</date><risdate>1997</risdate><volume>45</volume><issue>6</issue><spage>747</spage><epage>751</epage><pages>747-751</pages><issn>0002-8614</issn><eissn>1532-5415</eissn><coden>JAGSAF</coden><abstract>OBJECTIVE: To determine whether simultaneous administration of dehydroepiandrosterone sulfate (DHEAS) exhibits adjuvant activity in the immune response of aging humans by supplementing influenza vaccination with the maximum single dose of DHEAS that could be practically injected subcutaneously (approximately 7.5 mg). DESIGN: A randomized, double‐blind, placebo‐controlled trial of DHEAS injection with 1993–94 and 1994–95 influenza vaccine in older subjects. In addition, initial safety, tolerability, and control testing with 1993–94 influenza vaccine was conducted in young subjects. SETTING: An urban primary care geriatrics clinic. PARTICIPANTS: Seventy‐eight older adult volunteers (mean age 78.61 ± 3.43 years, range 73–90 years) and 20 younger controls (&lt;40 years, means age 32.76 ± 5.39 years) were recruited from clinic and community advertising. Subjects were free of disease or medication known to affect immune function. MEASUREMENTS: Immune responses to vaccine at 0, 2, and 4 weeks were measured by vaccine antigen‐induced lymphoproliferation in peripheral blood mononuclear cells (PBMC) and serum antibody response by hemagglutination inhibition (HI). RESULTS: The maximum DHEAS dose that could be practically administered subcutaneously was 7.5 mg. Baseline DHEAS levels were significantly lower in older adults (52.1 vs 236.4 μg/dL, P &lt; .001). The 1993 old adult DHEAS group HI response tended to be higher for the H3N2 Beijing antigen but not for the H1N1 or B antigen. In subjects with HI titers less then 1:40 for the H3N2 Beijing antigen (n = 29), the post‐vaccination titer response tended to be higher among the 16 subjects who received DHEAS (P = .06). The peak response for the H3N2 antigen was associated with the initial DHEAS serum concentration in the DHEAS and placebo groups (R2 =.22, P = .04 and R2 = .21, P = .06, respectively). No significant differences were found for antibody responses to the H1N1 and B antigens or vaccine‐antigen induced lymphoproliferation. CONCLUSION: A one‐time supplemental dose of DHEAS with influenza vaccination appeared to enhance the specific HI antibody response to the 1993–94 H3N2 antigen in a small group of older adults. These findings were limited to those with lower prevaccination titers and lower DHEAS concentrations. Although clinical implications of these findings for influenza vaccine are uncertain, these results suggest additional detailed immunologic investigations on the role of DHEAS in the aging human immune response are warranted.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>9180672</pmid><doi>10.1111/j.1532-5415.1997.tb01482.x</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0002-8614
ispartof Journal of the American Geriatrics Society (JAGS), 1997-06, Vol.45 (6), p.747-751
issn 0002-8614
1532-5415
language eng
recordid cdi_proquest_miscellaneous_79065648
source MEDLINE; Wiley Online Library All Journals
subjects Adult
Aged
Aging
Antibody Formation
Biological and medical sciences
Dehydroepiandrosterone Sulfate - immunology
Double-Blind Method
Epidemiology. Vaccinations
Female
General aspects
Hemagglutination
Hormones. Endocrine system
Humans
Infectious diseases
Influenza
Influenza Vaccines - therapeutic use
Influenza, Human - prevention & control
Male
Medical sciences
Older people
Pharmacology. Drug treatments
Placebos
Retrospective Studies
Vaccines
title The Effect of DHEAS on Influenza Vaccination in Aging Adults
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T04%3A02%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Effect%20of%20DHEAS%20on%20Influenza%20Vaccination%20in%20Aging%20Adults&rft.jtitle=Journal%20of%20the%20American%20Geriatrics%20Society%20(JAGS)&rft.au=Degelau,%20John&rft.date=1997-06&rft.volume=45&rft.issue=6&rft.spage=747&rft.epage=751&rft.pages=747-751&rft.issn=0002-8614&rft.eissn=1532-5415&rft.coden=JAGSAF&rft_id=info:doi/10.1111/j.1532-5415.1997.tb01482.x&rft_dat=%3Cproquest_cross%3E13670600%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=210372712&rft_id=info:pmid/9180672&rfr_iscdi=true